Eribulin

Generic Name
Eribulin
Brand Names
Halaven, Eribulin Baxter, Mevlyq
Drug Type
Small Molecule
Chemical Formula
C40H59NO11
CAS Number
253128-41-5
Unique Ingredient Identifier
LR24G6354G
Background

Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid ...

Indication

For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.

Associated Conditions
Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
Associated Therapies
-
Clinical Trials
Related News

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin

First Posted Date
2023-04-12
Last Posted Date
2024-12-20
Lead Sponsor
MedSIR
Target Recruit Count
14
Registration Number
NCT05810870
Locations
🇪🇸

Hospital Universitario Clínico San Cecilio de Granada, Granada, Andalucia, Spain

🇪🇸

Hospital Universitario Virgen del Rocio, Sevilla, Andalucia, Spain

🇪🇸

Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain

and more 10 locations

EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

First Posted Date
2022-11-17
Last Posted Date
2024-02-08
Lead Sponsor
Australia New Zealand Gynaecological Oncology Group
Target Recruit Count
30
Registration Number
NCT05619913
Locations
🇦🇺

Prince of Wales Hospital, Randwick, New South Wales, Australia

🇬🇧

Imperial College London, London, United Kingdom

🇦🇺

Royal Brisbane and Women's Hospital, Herston, Queensland, Australia

and more 3 locations

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

First Posted Date
2022-10-06
Last Posted Date
2024-11-27
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
55
Registration Number
NCT05570253
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

🇺🇸

BAPTIST ALLIANCE - MCI (Data Collection Only), Miami, Florida, United States

🇺🇸

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States

and more 5 locations

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

First Posted Date
2022-09-19
Last Posted Date
2022-09-19
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
40
Registration Number
NCT05546255
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer

First Posted Date
2022-09-07
Last Posted Date
2022-09-07
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
180
Registration Number
NCT05530057
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Phase 2
Recruiting
Conditions
Breast Cancer
Interventions
Drug: Tucatinib
Drug: Eribulin
Drug: Trastuzumab
First Posted Date
2022-07-14
Last Posted Date
2024-03-12
Lead Sponsor
Criterium, Inc.
Target Recruit Count
30
Registration Number
NCT05458674
Locations
🇺🇸

Cancer Care Northwest, Spokane Valley, Washington, United States

🇺🇸

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

🇺🇸

Swedish Cancer Institute, Issaquah, Washington, United States

and more 2 locations

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

First Posted Date
2022-06-02
Last Posted Date
2022-06-02
Lead Sponsor
Beijing 302 Hospital
Target Recruit Count
30
Registration Number
NCT05402722
Locations
🇨🇳

The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

First Posted Date
2022-05-16
Last Posted Date
2024-07-05
Lead Sponsor
AstraZeneca
Target Recruit Count
637
Registration Number
NCT05374512
Locations
🇬🇧

Research Site, Warwick, United Kingdom

SMMART Adaptive Clinical Treatment (ACT) Trial

Early Phase 1
Withdrawn
Conditions
Advanced Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Stage II Pancreatic Cancer AJCC v8
Stage III Ovarian Cancer AJCC v8
Advanced Prostate Carcinoma
Recurrent Adult Soft Tissue Sarcoma
Recurrent Breast Carcinoma
Stage IV Ovarian Cancer AJCC v8
Advanced Malignant Solid Neoplasm
Advanced Ovarian Carcinoma
Interventions
Drug: Alectinib
Drug: Alpelisib
Drug: Anastrozole
Biological: Atezolizumab
Biological: Bevacizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Capecitabine
Drug: Carboplatin
Drug: Cobimetinib
Drug: Entrectinib
Drug: Eribulin
Drug: Fulvestrant
Biological: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Drug: Irinotecan
Drug: Letrozole
Drug: Nab-paclitaxel
Drug: Niraparib
Drug: Olaparib
Drug: Paclitaxel
Drug: Palbociclib
Biological: Pertuzumab
Other: Quality-of-Life Assessment
Biological: Trastuzumab
Biological: Trastuzumab Emtansine
Drug: Vemurafenib
Drug: Vinorelbine
Drug: Vismodegib
First Posted Date
2022-02-14
Last Posted Date
2024-01-23
Lead Sponsor
OHSU Knight Cancer Institute
Registration Number
NCT05238831

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

First Posted Date
2022-01-25
Last Posted Date
2022-11-23
Lead Sponsor
Hunan Cancer Hospital
Target Recruit Count
80
Registration Number
NCT05206656
Locations
🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy